Smart deals start with the right connections.
Access 800+ qualified LPs through CQ’s Investor Database.
Overview and Management
Establishment Year
2018
Mission
To address the urgent need for new anti-infective therapies and combat antimicrobial resistance by investing in innovative solutions.
Values
Innovation, long-term commitment, collaboration, and public health impact.
Investment Roles
General Partner (GP)
Participant Demographics
Generational Wealth Planning
Risk Tolerance
Patient, long-term investment approach with flexible terms.
References or Case Studies
Minervax ApS and Spero Therapeutics, two companies in the portfolio, have achieved clinical proof of concept.
Team Experience
Notable Achievements
Two projects, Minervax ApS and Spero Therapeutics, achieved clinical proof of concept.
Project Track Record
Investments in 10 global companies focusing on antimicrobial resistance therapies.
Exit Strategies
Legal, Compliance and Contact Information
Regulatory Registrations
Compliance History
repair@novo.dk
Phone Number
Address
Hellerup Denmark